Accelerating progress to innovation for patients: Trial design and risk stratification☆
Under a Creative Commons license
open access
Keywords
Neoadjuvant therapy
Triple-negative breast cancer
Immune checkpoint inhibitors
Hormone receptor-positive breast cancer
Phase 3 trials
Cited by (0)
- ☆
This article is published as part of a supplement supported by St. Gallen Oncology Conferences.
© 2021 Published by Elsevier Ltd.